Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Rating of “Moderate Buy” by Analysts

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $138.1667.

A number of equities analysts have weighed in on CORT shares. HC Wainwright boosted their target price on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research note on Monday, July 27th. Finally, Weiss Ratings raised Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $122.25 on Monday. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $123.44. The company has a market capitalization of $13.22 billion, a price-to-earnings ratio of 291.08 and a beta of 0.45. The stock’s 50 day moving average is $97.39 and its two-hundred day moving average is $64.76.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.29 EPS. On average, analysts predict that Corcept Therapeutics will post 1.77 earnings per share for the current year.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks sharply raised long-term earnings forecasts. The firm increased its FY2026 EPS estimate to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also raised, including Q1 2027 to $0.11 from a projected loss of $0.17 and Q2 2028 to $1.17 from $0.69. These revisions signal expectations for accelerating profitability.
• Positive Sentiment: Recent operating results provide support for the bullish outlook. Corcept’s latest reported quarter produced $0.36 in EPS versus the $0.02 consensus estimate, while revenue of $256.15 million exceeded expectations of $221.15 million and grew 31.7% year over year.
• Positive Sentiment: Analyst sentiment and price targets remain constructive. Recent coverage includes Buy or Overweight ratings and price targets ranging from $150 to $165, while the reported consensus rating is “Moderate Buy” with a $138.17 target. An investment analysis also argued that the launch of Lifyorli and continued Korlym growth could drive revenue growth, margin expansion and further EPS upside. Like The Knicks, Corcept Rebounded And Is Crushing It
• Neutral Sentiment: Zacks maintained a “Hold” rating. The improved earnings estimates are encouraging, but the unchanged rating suggests the analyst views the stock’s substantial rally and high valuation as partly reflected in the price.
• Negative Sentiment: Director David Mahoney sold 103,606 shares for approximately $12.25 million. The transaction reduced his ownership by 8.37%, although he still retained more than 1.13 million shares. The sale could create short-term sentiment pressure, but it does not necessarily indicate a change in the company’s fundamentals. Insider Selling: Corcept Therapeutics Director Sells Stock

Insider Buying and Selling

In other news, Director David L. Mahoney sold 103,606 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total transaction of $12,251,409.50. Following the sale, the director owned 1,133,539 shares in the company, valued at $134,040,986.75. This represents a 8.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sean Maduck sold 75,000 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the sale, the insider directly owned 8,977 shares in the company, valued at $588,801.43. This trade represents a 89.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 520,146 shares of company stock worth $48,903,764 over the last 90 days. Company insiders own 20.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pathstone Holdings LLC lifted its position in Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after acquiring an additional 144 shares in the last quarter. State of Wyoming increased its holdings in Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 186 shares in the last quarter. Gould Capital LLC raised its stake in shares of Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Corcept Therapeutics by 3.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 247 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 248 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.